Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses
caregivers, and often results in prescriptions for harmful antipsychotics. Effective
treatments are lacking because of limited knowledge of the etiology of nighttime agitation.
The investigators propose a clinical trial to better elucidate whether a sleep disorder,
restless legs syndrome, may be a mechanism for nighttime agitation, and if treatment with
gabapentin enacarbil (Horizant®) reduces nighttime agitation, improves sleep, reduces
restless legs syndrome behaviors, and reduces antipsychotic medications.